Director, Market Access Pipeline & Readiness
Regeneron Pharmaceuticals
Summary
This role requires a skilled strategist with excellent leadership capabilities to shape the direction of multiple pipeline assets. You will represent the payer voice for the assets you cover and will be accountable to define (and prepare for) successful reimbursement and patient access. This role is part of the Market Access Pipeline & Readiness Team, which is part of the Market Access Business Unit. We are seeking a highly collaborative individual who will work cohesively within the cross-functional team that includes New Product (marketing), HEOR, Medical Affairs, Clinical and Regulatory. For programs that are nearing launch you will serve as the nexus between these stakeholders and other functions within the Inline Market Access Business Unit (Trade, Patient Support, Pricing) to ensure our launch plans reflect their expertise – ultimately leading to a smooth transition for launch. Considering the growing Regeneron pipeline, company expansion and collaboration announcements, this role requires you to be comfortable operating autonomously within a growing and evolving company. You will be expected to proactively identify and resolve the opportunities and challenges to achieve the desired business objectives. This includes a commitment to working well together, which is a core value at Regeneron.
Job description
When & where
In the Sleepy Hollow, NY office 4 days a week
Discover your role
The Director of Market Access Pipeline & Readiness will work closely with the New Products (Commercial) Lead to inform the market access / payer perspective for key deliverables within the Development decision-making framework. Importantly, the Director will also be responsible for providing assumptions, and associated rationale, incorporated into program forecasts. Each member of the Market Access Pipeline & Readiness Team is assigned multiple assets that range from pre-phase one to filing. Therefore, specific accountabilities will vary by asset; you will be expected to:
- Incorporate timely payer insight and perspectives into commercial planning and clinical development for assets
- Analyze trends and/or changes in the global market access environment, including competitors, to determine the strategic implications for the pipeline assets
- Create and lead strategic market access and pricing plans for pipeline assets, with focus on US, EU and Japan
- Ensure development plans will deliver a compelling payer value proposition(s) to achieve the target reimbursement
- Advise cross-functional team on options for early engagement with HTA authorities with clear recommendations on the insight / knowledge gaps to address, then execute on recommendations
- Identify clinical and economic evidence needs to achieve target reimbursement; ensure that there is a plan in place to address evidence gaps
- Lead the development of market access tools for near-launch assets including global value proposition, objection handlers, launch readiness plans
- Plan for early and expanded access programs in partnership with the development team and patient advocacy
- Provide input as needed on internal needs (e.g., forecasting and business development initiatives)
This role requires
- 12+ years of relevant professional experience (e.g. pharmaceutical/biotech, consulting, healthcare reimbursement)
- Ideal candidate will have both significant US and global market access experience
- Ideal candidate will have significant experience with specialty products across a broad array of therapy areas including I&I, CV, obesity, rare diseases
- Strong knowledge of the stakeholders and reimbursement dynamics in key payer systems (e.g., US, FRA, GER, UK)
- Record of accomplishment of building productive working relationships with internal stakeholders
- Previous experience working in and leading a matrix team
- Demonstrated initiative, critical thinking skills, and an ability to work effectively in complex environments
- Excellent verbal and written communication skills
- Bachelor’s degree in life science, economics, health economics or related discipline required, advanced degree strongly preferred
Requirements
- 12+ years of relevant professional experience (e.g. pharmaceutical/biotech, consulting, healthcare reimbursement)
- Ideal candidate will have both significant US and global market access experience
- Ideal candidate will have significant experience with specialty products across a broad array of therapy areas including I&I, CV, obesity, rare diseases
- Strong knowledge of the stakeholders and reimbursement dynamics in key payer systems (e.g., US, FRA, GER, UK)
- Record of accomplishment of building productive working relationships with internal stakeholders
- Previous experience working in and leading a matrix team
- Demonstrated initiative, critical thinking skills, and an ability to work effectively in complex environments
- Excellent verbal and written communication skills
- Bachelor’s degree in life science, economics, health economics or related discipline required, advanced degree strongly preferred
Benefits
- Annual Bonuses
- Incentive Plans
- Equity Awards
- Pension or Retirement Benefits
- 401(k) Company Match
- Health and Wellness Programs
- Fitness Centers
- Medical Insurance
- Dental Insurance
- Vision Insurance
- Life Insurance
- Disability Insurance
- Paid Time Off
- Family Support Benefits
Company overview
Regeneron Pharmaceuticals is a leading American biotechnology company founded in 1988 and headquartered in Tarrytown, New York. The company specializes in inventing, developing, and commercializing life-transforming medicines for people with serious diseases. Regeneron is renowned for its innovative antibody technologies and has developed several groundbreaking therapies, including EYLEA® for retinal diseases, DUPIXENT® for inflammatory conditions, and the COVID-19 antibody cocktail REGEN-COV®. The company operates with a strong focus on research and development across multiple therapeutic areas including ophthalmology, oncology, cardiovascular diseases, and rare genetic disorders. Regeneron's proprietary VelocImmune® technology platform enables the rapid generation of fully human monoclonal antibodies. With over 15,000 employees globally and annual revenues exceeding $14 billion, Regeneron has established itself as a major force in the biotechnology industry, consistently ranking among the top-performing pharmaceutical companies and maintaining a robust pipeline of investigational therapies.